The incorporation of CDK4/6i into treatment regimens for HR+/HER2- advanced breast cancer has significantly improved clinical outcomes, demonstrating benefits in progression-free survival (PFS), objective response rate (ORR), overall survival (OS), and quality of life (5). This evidence concerns the gene ERBB2 and breast carcinoma.